Vaccination in HIV-infected Adults

Overview

Journal AIDS Patient Care STDS

Specialty Infectious Diseases

Date 2014 Jul 17

PMID 25029589

Citations 40

Authors

Nancy F Crum-Cianflone

Mark R Wallace

Affiliations

Soon will be listed here.

Abstract

Vaccines are critical components for protecting HIV-infected adults from an increasing number of preventable diseases. However, missed opportunities for vaccination among HIV-infected persons persist, likely due to concerns regarding the safety and efficacy of vaccines, as well as the changing nature of vaccine guidelines. In addition, the optimal timing of vaccination among HIV-infected adults in regards to HIV stage and receipt of antiretroviral therapy remain important questions. This article provides a review of the current recommendations regarding vaccines among HIV-infected adults and a comprehensive summary of the evidence-based literature of the benefits and risks of vaccines among this vulnerable population.

Citing Articles

Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study.

Yue W, Zhai P, Mao J, Ma J, Ren W, Jiang T BMJ Public Health. 2025; 2(2):e001042.

PMID: 40018595 PMC: 11816706. DOI: 10.1136/bmjph-2024-001042.

The Current Status in Terms of Vaccination for Individuals Infected with Human Immunodeficiency Virus.

Xu N, Shen Y, Huang W, Nie J Viruses. 2025; 17(2).

PMID: 40006926 PMC: 11860447. DOI: 10.3390/v17020171.

Understanding human papillomavirus vaccine response and efficacy in people living with HIV: A systematic mixed studies review and meta-analysis.

Akumbom A, Bergman A, Strickler H, Budhathoki C, Nkimbeng M, Grant R PLOS Glob Public Health. 2024; 4(12):e0003931.

PMID: 39705286 PMC: 11661617. DOI: 10.1371/journal.pgph.0003931.

Inflammation and Microbial Translocation Correlate with Reduced MAIT Cells in People with HIV.

Ryu A, Clagett B, Freeman M Pathog Immun. 2024; 10(1):19-46.

PMID: 39635460 PMC: 11613984. DOI: 10.20411/pai.v10i1.746.

Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa.

Dlamini S, Madhi S, Muloiwa R, von Gottberg A, Moosa M, Meiring S South Afr J HIV Med. 2024; 19(1):839.

PMID: 39449989 PMC: 11500477. DOI: 10.4102/sajhivmed.v19i1.839.

References

Louie J, Shaikh-Laskos R, Preas C, Nguyen V, Peters A, Messenger S . Re-emergence of another vaccine-preventable disease?-Two cases of rubella in older adults. J Clin Virol. 2009; 46(1):98-100. DOI: 10.1016/j.jcv.2009.06.013. View

Kengsakul K, Sathirapongsasuti K, Punyagupta S . Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002; 85(1):131-4. View

Ion-Nedelcu N, Dobrescu A, Strebel P, Sutter R . Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet. 1994; 343(8888):51-2. DOI: 10.1016/s0140-6736(94)90903-2. View

Kim H, Harrington R, Crane H, Dhanireddy S, Dellit T, Spach D . Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009; 20(9):595-600. DOI: 10.1258/ijsa.2009.009126. View

Rock C, de Barra E, Sadlier C, Kelly S, Dowling C, McNally C . Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health. 2013; 6(3):173-8. DOI: 10.1016/j.jiph.2012.11.001. View

. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep. 1996; 45(28):603-6. View

Siberry G, Warshaw M, Williams P, Spector S, Decker M, Jean-Philippe P . Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2011; 31(1):47-52. PMC: 3252429. DOI: 10.1097/INF.0b013e318236c67b. View

Tedaldi E, Baker R, Moorman A, Wood K, Fuhrer J, McCabe R . Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004; 38(10):1478-84. DOI: 10.1086/420740. View

Gebo K, Kalyani R, Moore R, Polydefkis M . The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2005; 40(2):169-74. DOI: 10.1097/01.qai.0000178408.62675.b0. View

10.

Kunisaki K, Janoff E . Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8):493-504. PMC: 2775097. DOI: 10.1016/S1473-3099(09)70175-6. View

11.

Sullivan P, Hanson D, Dworkin M, Jones J, Ward J . Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS. 2000; 14(17):2781-5. DOI: 10.1097/00002030-200012010-00018. View

12.

Farley M, Stephens D, Brachman Jr P, Harvey R, Smith J, Wenger J . Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med. 1992; 116(10):806-12. DOI: 10.7326/0003-4819-116-10-806. View

13.

Pistone T, Verdiere C, Receveur M, Ezzedine K, Lafon M, Malvy D . Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res. 2010; 8(6):461-6. DOI: 10.2174/157016210793499277. View

14.

Atashili J, Kalilani L, Adimora A . Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis. 2006; 6:138. PMC: 1574329. DOI: 10.1186/1471-2334-6-138. View

15.

French N, Gordon S, Mwalukomo T, White S, Mwafulirwa G, Longwe H . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362(9):812-22. PMC: 2873559. DOI: 10.1056/NEJMoa0903029. View

16.

Sheng W, Kao J, Chen P, Huang L, Chang S, Sun H . Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007; 45(9):1221-9. DOI: 10.1086/522173. View

17.

King Jr J, Treanor J, Fast P, Wolff M, Yan L, Iacuzio D . Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000; 181(2):725-8. DOI: 10.1086/315246. View

18.

Miotti P, Nelson K, Dallabetta G, Farzadegan H, Margolick J, Clements M . The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989; 262(6):779-83. View

19.

Kroon F, van Dissel J, Ravensbergen E, Nibbering P, Van Furth R . Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2000; 19(7-8):886-94. DOI: 10.1016/s0264-410x(00)00232-2. View

20.

Wallace M, Brandt C, Earhart K, Kuter B, Grosso A, Lakkis H . Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis. 2004; 39(8):1207-13. DOI: 10.1086/424666. View